51
|
Wick M, Meade J, Vaught T, Nehls M, Flores J, Kaufman J, Tolcher A, Rasco D, Patnaik A, Moskaluk C, Papadopoulos K. 97 Utilization of low passage adenoid cystic carcinoma PDX models to identify novel combination therapies. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70223-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
52
|
Wick M, Meade J, Nehls M, Vaught T, Carlile J, Tolcher A, Rasco D, Patnaik A, Papadopoulos K. 18 Establishment and characterization of a Merkel Cell carcinoma PDX panel: Screening for potentially useful therapies. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70144-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
53
|
Daud A, Hamid O, Robert C, Hodi F, Wolchok J, Hwu W, Weber J, Kefford R, Hersey P, Joshua A, Joseph R, Gangadhar T, Dronca R, Patnaik A, Zarour H, Gerigich K, Lunceford J, Emancipator K, Dolled-Filhart M, Li X, Kang P, Ebbinghaus S, Ribas A. 140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475). Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70266-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
54
|
Garon E, Gandhi L, Rizvi N, Hui R, Balmanoukian A, Patnaik A, Eder J, Blumenshein G, Aggarwal C, Soria JC, Ahn M, Gubens M, Ramalingam S, Johnson E, Arkenau H, Lubiniecki G, Zhang J, Rutledge R, Emancipator K, Leighl N. Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu438.51] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
55
|
Robert C, Joshua A, Weber J, Ribas A, Hodi F, Kefford R, Daud A, Wolchok J, Hwu WJ, Gangadhar T, Patnaik A, Hersey P, Dronca R, Zarour H, Ge Y, Lindia J, Giannotti M, Ebbinghaus S, Kang S, Hamid O. Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu438.42] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
56
|
Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. Br J Cancer 2014; 111:272-80. [PMID: 24901237 PMCID: PMC4102944 DOI: 10.1038/bjc.2014.290] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2014] [Revised: 04/25/2014] [Accepted: 05/07/2014] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Ficlatuzumab, a humanised hepatocyte growth factor (HGF) IgG1κ inhibitory monoclonal antibody, was evaluated for recommended phase II dose (RP2D), safety, pharmacokinetics (PKs), antidrug antibody (ADA), pharmacodynamics (PDs) and antitumour activity as monotherapy or combined with erlotinib. METHODS Patients with solid tumours received ficlatuzumab 2, 5, 10 or 20 mg kg(-1) intravenously every 2 weeks (q2w). Additional patients were treated at the RP2D erlotinib. RESULTS Forty-one patients enrolled at doses ⩽20 mg kg(-1). Common adverse events (AEs) included peripheral oedema, fatigue and nausea. Three patients experienced grade ⩾3 treatment-related hyperkalaemia/hypokalaemia, diarrhoea or fatigue. Best overall response (44%) was stable disease (SD); median duration was 5.5 months (0.4-18.7 months). One patient has been on therapy with SD for >4 years. Pharmacokinetics of ficlatuzumab showed low clearance (0.17-0.26 ml h(-1) kg(-1)), a half-life of 6.8-9.4 days and dose-proportional exposure. Ficlatuzumab/erlotinib had no impact on the PK of either agent. No ADAs were detected. Ficlatuzumab increased serum HGF levels. CONCLUSIONS Recommended phase II dose is 20 mg kg(-1) q2w for ficlatuzumab monotherapy or with erlotinib. Preliminary antitumour activity and manageable AEs were observed. Pharmacokinetics were dose-proportional and consistent with other IgG therapeutics. Ficlatuzumab was not immunogenic, and serum HGF was a potential PD marker.
Collapse
|
57
|
Gangil B, Patnaik A, Kumar A. Evaluation of Thermo-Mechanical and Wear Behavior of Short Carbon Fibre Vinyl-Ester Filled Homogenous and Their Functionally Graded Composites. INT POLYM PROC 2013. [DOI: 10.3139/217.2682] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Abstract
The paper presents the processing and mechanical characterization of chopped carbon fibre reinforced homogenous and functionally graded vinyl ester composites and also reports on their sliding wear characteristics respectively. The sliding wear characteristics are studied with the help of POD test employing the design of experiments approach based on Taguchi's orthogonal arrays. Dynamic mechanical analysis is carried out of the investigated homogenous/FGMs composites to investigate the overall stiffness/flexibility, so as to improve the specific wear rate. Present study reveals that graded composite possess good mechanical and wear characteristics compared to homogenous composites. SEM confirms the graded dispersion of carbon fibre in the matrix.
Collapse
|
58
|
Patnaik A, Satapathy A, Mahapatra SS, Dash RR. Erosive Wear Assesment of Glass Reinforced Polyester-Flyash Composites Using Taguchi Method. INT POLYM PROC 2013. [DOI: 10.3139/217.2113] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Abstract
Experiments are conducted to study the solid particle erosion wear behavior of glass reinforced polyester composites with flyash as a filler material. This study makes use of a methodology based on Taguchi's experimental design approach to characterize the erosion response of these composites. The procedure eliminates the need for repeated experiments and thus saves time, materials and cost. It identifies not only the significant control factors but also their interactions influencing the erosion rate predominantly. From the experimental findings an optimal combination of control factors is obtained on the basis of a proposed predictive model. This model is validated by performing a confirmation experiment with an arbitrarily chosen set of factor combination. Finally, optimal factor settings for minimum wear rate under specified experimental conditions have been determined using genetic algorithm.
Collapse
|
59
|
Wick M, Thangasamy A, Gamez L, Brown J, Chavez R, Tolcher A, Patnaik A, Rodriguez L, Mangold G, Papadopoulos K. 60 Patient-derived Xenograft (PDX) Models of EML4-ALK-driven Non-small Cell Lung Cancer: Development, Characterization and Clinical Correlation Analysis. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71858-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
60
|
Wick M, Vaught T, Thangasamy A, Meade J, Tolcher A, Patnaik A, Smith L, Drengler R, White A, Papadopoulos K. 189 Establishment, Characterization and in Vivo Evaluation of Preclinical Tumor Models to Elucidate Differential Response to EGFR-targeted Therapies. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71987-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
61
|
Smith D, Chugh R, Patnaik A, Papadopoulos K, Chambers G, Thorpe V, Xu L, Kapoun A, Dupont J, Tolcher A. 28 A First-in-human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advanced Solid Tumors. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71827-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
62
|
Rasco D, Patnaik A, Amaya A, Gaylor S, Moore T, Izbicka E, Streeper R, Rodrigueza W, Messmann R, Tolcher A. 620 A Study of PNT2258 (DNA-targeted Blocker of BCL2 Expression) in Patients with Advanced Solid Tumors. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72417-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
63
|
Tolcher A, Kapoun A, Wang M, Zhang C, Patnaik A, Papadopoulos K, Chugh R, Thorpe V, Dupont J, Smith D. 314 Biomarker Analysis in the First-in-human OMP-59R5 (anti-Notch2/3) Phase I Study Demonstrates Pharmacodynamic (PD) Modulation of the Notch Pathway in Patients with Advanced Solid Tumors. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72112-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
64
|
Chi KN, Tolcher A, Lee P, Rosen PJ, Kollmannsberger CK, Papadopoulos KP, Patnaik A, Molina A, Jiao J, Pankras C, Kaiser B, Bernard A, Tran N, Acharya M. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 2012; 71:237-44. [PMID: 23064959 DOI: 10.1007/s00280-012-2001-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2012] [Accepted: 09/29/2012] [Indexed: 10/27/2022]
Abstract
PURPOSE To assess the effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan HBr (CYP2D6 substrate) and theophylline (CYP1A2 substrate) in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS Men with progressive metastatic mCRPC who failed gonadotropin-releasing hormone therapy and ≥1 lines of chemotherapy were enrolled. Patients received two doses of dextromethorphan HBr-30 mg (n = 18; group A) or theophylline-100 mg (n = 16; group B) under fasting conditions; one dose on cycle 1, day -8, and the other dose on cycle 1, day 8. Only patients with extensive CYP2D6 metabolizing status were assigned to group A. All patients received continuous daily oral abiraterone acetate (1,000 mg) plus prednisone (10 mg) starting on cycle 1, day 1. RESULTS Coadministration of abiraterone acetate plus prednisone increased the systemic exposure of dextromethorphan by approximately 100%. Ratios of geometric means for maximum plasma concentration (C(max)) (275.36%) and area under plasma concentration-time curves from time 0 to 24 h (AUC(24h)) (268.14%) of dextromethorphan were outside the bioequivalence limit. The pharmacokinetics of theophylline was unaltered following coadministration of abiraterone acetate plus prednisone. Ratios of geometric means [C(max); 102.36% and AUC(24h); 108.03%] of theophylline exposure parameters were within the bioequivalence limit. The safety profile of abiraterone acetate was consistent with reported toxicities. CONCLUSION Abiraterone acetate plus prednisone increased the exposure of dextromethorphan, suggesting a need for caution when coadministrating with known CYP2D6 substrates. The pharmacokinetics of theophylline was unaffected when coadministered with abiraterone acetate plus prednisone.
Collapse
|
65
|
Beeram M, Papadopoulos K, Tolcher A, Rasco D, Cousin T, Itri L, Patnaik A. Tesetaxel: Analysis of Two Dosing Schedules (ONCE WEEKLY VS. EVERY 3 WEEKS) Using a Novel Oral Taxane. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33042-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
66
|
Patnaik A, Papadopoulos K, Tolcher A, Beeram M, Tawashi M, Fournel M, Maroun C, Humphrey R, Besterman J, O'Dwyer P. Clinical Effects of MGCD265, an oral Tyrosine Kinase Inhibitor, in Combination with Erlotinib or Docetaxel for Treatment of Advanced Gastroesophageal and Nsclc Tumors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33054-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
67
|
Schwartzberg L, Rubin P, Patnaik A, Itri L, Olson AL, Seidman AD. P5-19-11: Tesetaxel, an Oral Taxane, as First-Line Therapy for Women with Metastatic Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-19-11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Parenteral taxanes (docetaxel, paclitaxel) are among the most active agents in treating metastatic breast cancer (MBC). However, their use is limited by inherent or acquired multidrug resistance, hypersensitivity, and neurotoxicity. Tesetaxel is an advanced-generation, orally available taxane that is formulated as a capsule for oral administration and has a long terminal half-life in plasma (∼180 hrs). Unlike standard taxanes, tesetaxel is not a substrate for P-glycoprotein (P-gp), a major cause of taxane resistance. The drug is highly concentrated in cells that overexpress P-gp. In taxane-resistant breast cancer xenografts (DU4475), tesetaxel induced a 94% reduction in tumor size, substantially exceeding the activity of docetaxel and paclitaxel (46% and 26%, respectively). Neurotoxicity was also substantially lower with tesetaxel compared with equi-myelotoxic doses of docetaxel. Among more than 350 patients (pts), there have been no occurrences of hypersensitivity reactions. An initial phase 2 study as 2nd-line therapy for pts with MBC who progressed after multidrug anthracycline-containing regimens showed a 38% partial response (PR) rate using tesetaxel Q3 wks at a dose of 27–35 mg/m2. We conducted a Phase 2, open-label, multicenter study of the efficacy and safety of tesetaxel as first-line therapy in women with MBC.
Methods: Eligible pts have Stage IV, HER2−negative MBC; ECOG PS 0–1; and adequate organ function. No prior chemotherapy is allowed (other than 1 regimen in the adjuvant setting). Tesetaxel was administered orally Q3 wks at a starting dose of 27 mg/m2 with escalation to 35 mg/m2 as tolerated. No premedication for potential hypersensitivity was used. RECIST response rate was the primary endpoint. A Simon min-max two-stage design was used with a target response rate of 30% in 25 pts.
Results: To date, 20 women have been enrolled and treated. The median age was 62 years (range, 45–78). Time from diagnosis was > 4 years in 5 pts and ≤ 4 years in 6; MBC was newly diagnosed in the remaining 9. Hormone receptor status was triple negative in 5 pts at diagnosis and 10 at the time of metastasis. The most common sites of metastasis were lung (13 pts) and bone (9). Prior treatment included hormonal therapy in 13 pts, adjuvant chemotherapy in 16 (most commonly, ACT), and radiotherapy in 9. Of 11 pts currently evaluable for response, PR was achieved in 6 (55%), with confirmation of response in 4 and an ongoing PR in 1 of the 2 pts with an unconfirmed PR. SD was observed in 2 and disease progression in 3. Neutropenia was the most common adverse event, affecting 50% of pts; Grade 3–4 occurrences were observed most often after escalation of the tesetaxel dose to 35 mg/m2. Single occurrences (Grade 1) of neuropathy and nail changes were reported. There were no occurrences of hypersensitivity.
Conclusions: Tesetaxel overcomes multiple disadvantages of standard parenteral taxanes and is highly active in 1st- and 2nd-line MBC. To date, overall response rates in these settings are 55% and 38%, respectively. In view of this, we have amended the trial to expand the initial cohort. Potential schedule-dependency will be examined in a future cohort with a newly developed weekly-times-3 schedule. Updated results in both cohorts will be presented.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-19-11.
Collapse
|
68
|
Weekes CD, LoRusso P, Ramakrishnan V, Shih LM, Darbonne WC, Hegde P, Xin Y, Yu R, Xiang H, Brachmann RK, Patnaik A. A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3050] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
69
|
Sullivan D, Patnaik A, Papadopoulos KP, McCrea JB, Cerchio K, Li X, Stroh M, Orford KW, Trucksis M, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher AW. To assess the effect of ridaforolimus on the QTc interval in patients with advanced cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
70
|
O'Dwyer PJ, Papadopoulos KP, Tolcher AW, Teitelbaum UR, Harlacker K, Beeram M, Sohal D, Mehran M, Tawashi M, Drouin MA, Maroun CR, Wang J, Fournel M, Karam A, Besterman JM, Patnaik A. MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3083] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
71
|
Sankhala KK, Tolcher AW, Mita MM, Gordon MS, Rosen LS, Papadopoulos KP, Patnaik A, Drengler RL, Mita AC, Sarantopoulos J, Bristow RG, Fine G, Choy GS, Azab M. Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
72
|
Beeram M, Tolcher AW, Papadopoulos KP, Lang A, Smith L, Drengler R, Qureshi A, Patnaik A. Tesetaxel: Development of a weekly dosing schedule for an oral advanced-generation taxane. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
73
|
Yap TA, Yan L, Patnaik A, Olmos D, Fearen I, Baird RD, Papadopoulos KP, Tunariu N, Biondo A, Keilhack H, Delgado LM, Taylor A, Blackman SC, Carpenter CL, Decordova S, Heaton S, Garrett MD, Sullivan D, De Bono JS, Tolcher AW. Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
74
|
Tolcher AW, Baird RD, Patnaik A, Moreno Garcia V, Papadopoulos KP, Garrett CR, Olmos D, Shannon KA, Zazulina V, Rubin EH, Smith IC, Ryan J, Smith PD, Taylor A, Learoyd M, Lupinacci L, Yan L, De Bono JS. A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3004] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
75
|
Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Alvarez C, Mangold GL, Patnaik A. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study: The START Center experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2502] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|